S. Korea's Medipost Licenses Stem-Cell Drug To India's Alkem Labs
This article was originally published in PharmAsia News
Executive Summary
South Korea's Medipost and Alkem Laboratories of India signed a licensing agreement for distribution and marketing rights of the Cartistem cartilage-repair treatment based on stem cells.